[go: up one dir, main page]

AR078797A1 - Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc - Google Patents

Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc

Info

Publication number
AR078797A1
AR078797A1 ARP100103948A ARP100103948A AR078797A1 AR 078797 A1 AR078797 A1 AR 078797A1 AR P100103948 A ARP100103948 A AR P100103948A AR P100103948 A ARP100103948 A AR P100103948A AR 078797 A1 AR078797 A1 AR 078797A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
pharmaceutical compositions
caseina
quinasa
Prior art date
Application number
ARP100103948A
Other languages
English (en)
Inventor
Travis T Wager
Chakrapani Subramanyam
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR078797A1 publication Critical patent/AR078797A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer también las composiciones farmacéuticas, los procedimientos de tratamiento, los procedimientos de síntesis y los productos intermedios correspondiente Reivindicacion 1: Un compuesto de formula (1): o sus sales farmacéuticamente aceptables caracterizado porque: A es un heterocicloalquilo de 4 a 7 miembros que contiene nitrogeno o, alternativamente, A se puede condensar directamente con el anillo al cual está unido mediante R1; L es alquilo C1-3; R1 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; cada R2 es independientemente alquilo C1-3, fluor, hidroxilo, alcoxi C1-3 o ciano; R3 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; R4 es un heteroarilo de 5 a 10 miembros con de 1 a 3 heteroátomos, sustituido opcionalmente con de uno a tres sustituyentes R7; R5 es hidrogeno o -N(R8)2; R6 es hidrogeno, halogeno o alquilo C1-3; cada R7 es independientemente halogeno, (CH2)t-Fq, alquilo C1-3, -CF3, -(CH2)t-cicloalquilo C3-4, -(CH2)t-O-alquilo C1-3, -(CH2)t-ciano o -(CH2)t-hidroxi; Z es N o CR9; cada R8 es independientemente hidrogeno o alquilo C1-3; R9 es hidrogeno, alquilo C1-3 o halogeno; m es 0, 1 o 2; n es 0, 1 o 2; q es 1, 2 o 3; t es 0, 1 o 2.
ARP100103948A 2009-10-28 2010-10-28 Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc AR078797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28

Publications (1)

Publication Number Publication Date
AR078797A1 true AR078797A1 (es) 2011-12-07

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103948A AR078797A1 (es) 2009-10-28 2010-10-28 Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc

Country Status (22)

Country Link
US (1) US8518944B2 (es)
EP (1) EP2493876B1 (es)
JP (1) JP5784620B2 (es)
KR (1) KR101421852B1 (es)
CN (1) CN102686580B (es)
AR (1) AR078797A1 (es)
AU (1) AU2010311035B2 (es)
CA (1) CA2777632C (es)
DK (1) DK2493876T3 (es)
ES (1) ES2460065T3 (es)
HR (1) HRP20140252T1 (es)
IL (1) IL219190A0 (es)
IN (1) IN2012DN03182A (es)
MX (1) MX2012004997A (es)
PL (1) PL2493876T3 (es)
PT (1) PT2493876E (es)
RS (1) RS53246B (es)
SI (1) SI2493876T1 (es)
TW (1) TW201125864A (es)
UY (1) UY32977A (es)
WO (1) WO2011051858A1 (es)
ZA (1) ZA201202776B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
ES2623387T3 (es) * 2010-12-20 2017-07-11 Pfizer Inc. Nuevos compuestos de piridina condensada como inhibidores de la cinasa de caseína
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
CN105073751B (zh) 2012-12-21 2018-11-30 百时美施贵宝公司 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
JP6370294B2 (ja) * 2013-05-30 2018-08-08 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
SG11201606427SA (en) 2014-02-07 2016-09-29 Agency Science Tech & Res 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (ko) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 내이 지지 세포의 확장 및 분화 및 그의 사용 방법
WO2018201192A1 (en) * 2017-05-03 2018-11-08 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
CA3111848A1 (en) * 2018-09-09 2020-03-12 Qanatpharma Ag Use of casein kinase 1 inhibitors for treating vascular diseases
EP3877382A4 (en) * 2018-11-07 2022-07-27 The University of Melbourne NOVEL COMPOUNDS TO TREAT RESPIRATORY DISEASES
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
CN115298183A (zh) * 2020-03-27 2022-11-04 北京原基华毅生物科技有限公司 作为酪蛋白激酶抑制剂的化合物
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
AU2002316279B2 (en) * 2001-06-18 2007-08-23 The Rockefeller University Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
US7402672B2 (en) * 2003-12-11 2008-07-22 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
BRPI0514397A (pt) * 2004-08-19 2008-06-10 Aventis Pharma Inc derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JP5376950B2 (ja) * 2005-10-21 2013-12-25 エクセリクシス, インク. カゼインキナーゼii(ck2)モジュレーターとしてのピリミジオン類
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
ES2623387T3 (es) * 2010-12-20 2017-07-11 Pfizer Inc. Nuevos compuestos de piridina condensada como inhibidores de la cinasa de caseína

Also Published As

Publication number Publication date
PL2493876T3 (pl) 2014-06-30
AU2010311035A1 (en) 2012-05-03
PT2493876E (pt) 2014-03-20
IL219190A0 (en) 2012-06-28
CN102686580B (zh) 2014-09-10
CN102686580A (zh) 2012-09-19
IN2012DN03182A (es) 2015-09-25
JP5784620B2 (ja) 2015-09-24
WO2011051858A1 (en) 2011-05-05
KR101421852B1 (ko) 2014-07-22
CA2777632C (en) 2014-02-25
MX2012004997A (es) 2012-06-12
AU2010311035B2 (en) 2013-05-16
TW201125864A (en) 2011-08-01
ES2460065T3 (es) 2014-05-13
UY32977A (es) 2011-05-31
RS53246B (sr) 2014-08-29
EP2493876A1 (en) 2012-09-05
EP2493876B1 (en) 2014-02-12
DK2493876T3 (en) 2014-03-10
HRP20140252T1 (hr) 2014-04-25
US20110098272A1 (en) 2011-04-28
US8518944B2 (en) 2013-08-27
HK1171220A1 (en) 2013-03-22
KR20120088759A (ko) 2012-08-08
JP2013509392A (ja) 2013-03-14
CA2777632A1 (en) 2011-05-05
SI2493876T1 (sl) 2014-04-30
ZA201202776B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
AR078797A1 (es) Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR041170A1 (es) Derivados de bencimidazol, benzoxazol y benzotiazol
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR079636A1 (es) Antagonistas del receptor ccr2 y usos de los mismos
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
CL2020002253A1 (es) Derivados de 2,4 - diaminoquinazolina y usos médicos de los mismos.
CO6140030A2 (es) Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20091450A1 (es) INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal